Constitutional telomerase mutations are genetic risk factors for cirrhosis

Some patients with liver disease progress to cirrhosis, but the risk factors for cirrhosis development are unknown. Dyskeratosis congenita, an inherited bone marrow failure syndrome associated with mucocutaneous anomalies, pulmonary fibrosis, and cirrhosis, is caused by germline mutations of genes in the telomerase complex. We examined whether telomerase mutations also occurred in sporadic cirrhosis. In all, 134 patients with cirrhosis of common etiologies treated at the Liver Research Institute, University of Arizona, between May 2008 and July 2009, and 528 healthy subjects were screened for variation in the TERT and TERC genes by direct sequencing; an additional 1,472 controls were examined for the most common genetic variation observed in patients. Telomere length of leukocytes was measured by quantitative polymerase chain reaction. Functional effects of genetic changes were assessed by transfection of mutation‐containing vectors into telomerase‐deficient cell lines, and telomerase activity was measured in cell lysates. Nine of the 134 patients with cirrhosis (7%) carried a missense variant in TERT, resulting in a cumulative carrier frequency significantly higher than in controls (P = 0.0009). One patient was homozygous and eight were heterozygous. The allele frequency for the most common missense TERT variant was significantly higher in patients with cirrhosis (2.6%) than in 2,000 controls (0.7%; P = 0.0011). One additional patient carried a TERC mutation. The mean telomere length of leukocytes in patients with cirrhosis, including six mutant cases, was shorter than in age‐matched controls (P = 0.0004). Conclusion: Most TERT gene variants reduced telomerase enzymatic activity in vitro. Loss‐of‐function telomerase gene variants associated with short telomeres are risk factors for sporadic cirrhosis. (HEPATOLOGY 2011;)

[1]  Wei Zheng,et al.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 , 2010, Nature Genetics.

[2]  N. Young,et al.  Telomere diseases. , 2009, The New England journal of medicine.

[3]  S. Chanock,et al.  A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations , 2009, PloS one.

[4]  Qing Lan,et al.  Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. , 2009, Lung cancer.

[5]  T. Vulliamy,et al.  Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia , 2009, Human mutation.

[6]  Melissa Bondy,et al.  Genome-wide association study identifies five susceptibility loci for glioma , 2009, Nature Genetics.

[7]  Paolo Vineis,et al.  Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.

[8]  E. Estey,et al.  Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia , 2009, Proceedings of the National Academy of Sciences.

[9]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[10]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[11]  P. Lansdorp,et al.  Short telomeres are a risk factor for idiopathic pulmonary fibrosis , 2008, Proceedings of the National Academy of Sciences.

[12]  N. Young,et al.  Telomere maintenance and human bone marrow failure. , 2008, Blood.

[13]  Detlef Schuppan,et al.  Liver cirrhosis , 2008, The Lancet.

[14]  M. Blasco,et al.  Telomere length, stem cells and aging. , 2007, Nature chemical biology.

[15]  邓伟平,et al.  Dyskeratosis congenita , 2007 .

[16]  Chao Xing,et al.  Adult-onset pulmonary fibrosis caused by mutations in telomerase , 2007, Proceedings of the National Academy of Sciences.

[17]  N. Bache,et al.  Protein Composition of Catalytically Active Human Telomerase from Immortal Cells , 2007, Science.

[18]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[19]  N. Samani,et al.  Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study , 2007, The Lancet.

[20]  Olivia T. Abar,et al.  Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. , 2006, Gastroenterology.

[21]  Margaret A. Strong,et al.  Short Telomeres, even in the Presence of Telomerase, Limit Tissue Renewal Capacity , 2005, Cell.

[22]  E. Keeffe,et al.  Keratins as susceptibility genes for end-stage liver disease. , 2005, Gastroenterology.

[23]  E. Blackburn,et al.  Identification and functional characterization of 2 variant alleles of the telomerase RNA template gene (TERC) in a patient with dyskeratosis congenita. , 2005, Blood.

[24]  S. Chanock,et al.  Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. , 2005, The New England journal of medicine.

[25]  T. Vulliamy,et al.  Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC , 2004, Nature Genetics.

[26]  J. Satsangi,et al.  Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP‐2, with outcome of HCV infection , 2003, Hepatology.

[27]  P. Lansdorp,et al.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA , 2003, The Lancet.

[28]  A. Bosserhoff,et al.  A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. , 2003, Gastroenterology.

[29]  J. Ivanovich,et al.  Human telomerase RNA mutations and bone marrow failure , 2003, The Lancet.

[30]  D. Brenner,et al.  Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal , 2003, Hepatology.

[31]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, Gastroenterology.

[32]  M. Manns,et al.  Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis , 2002 .

[33]  T. Vulliamy,et al.  Association between aplastic anaemia and mutations in telomerase RNA , 2002, The Lancet.

[34]  R. Cawthon Telomere measurement by quantitative PCR. , 2002, Nucleic acids research.

[35]  T. Vulliamy,et al.  The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita , 2001, Nature.

[36]  E. Blackburn Switching and Signaling at the Telomere , 2001, Cell.

[37]  J. Satsangi,et al.  A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. , 2001, Gastroenterology.

[38]  Z. Goodman,et al.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.

[39]  D. Valla,et al.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. , 2001, The New England journal of medicine.

[40]  G. Davis,et al.  Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C , 2000, Hepatology.

[41]  I. Dokal,et al.  Dyskeratosis congenita in all its forms , 2000, British journal of haematology.

[42]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[43]  R. DePinho,et al.  Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. , 2000, Science.

[44]  M. Kaplan,et al.  Regression of Hepatic Fibrosis in Hepatitis C with Long-Term Interferon Treatment , 1998, Digestive Diseases and Sciences.

[45]  H. Esperou,et al.  Unusual complications after bone marrow transplantation for dyskeratosis congenita , 1998, British journal of haematology.

[46]  S. Klauck,et al.  X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions , 1998, Nature Genetics.

[47]  M. Kaplan,et al.  Reversibility of Hepatic Fibrosis in Autoimmune Hepatitis , 1997, Annals of Internal Medicine.

[48]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[49]  T R Hughes,et al.  Reverse transcriptase motifs in the catalytic subunit of telomerase. , 1997, Science.

[50]  S. Seki,et al.  Telomere shortening in chronic liver diseases. , 1995, Biochemical and Biophysical Research Communications - BBRC.

[51]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[52]  S. Kojima,et al.  Mutations in telomerase catalytic protein in Japanese children with aplastic anemia. , 2006, Haematologica.

[53]  I. Dokal,et al.  Dyskeratosis congenita. , 2006, Seminars in hematology.

[54]  A. Olovnikov [Principle of marginotomy in template synthesis of polynucleotides]. , 1971, Doklady Akademii nauk SSSR.

[55]  Olovnikov Am Principle of marginotomy in template synthesis of polynucleotides , 1971 .